Browse a selection of key resources and publications about our pipeline.

CLN-617 is an IL-2/IL-12 Fusion Protein With a Collagen-Anchoring Domain That Induces Potent Systemic Anti-Tumor Immunity Upon Intratumoral Administration (2022 AACR)

A Novel IgG-Based FLT3xCD3 Bispecific Antibody for the Treatment of AML and B-ALL (2022 JITC)

Mining for Tomorrow’s Cures: Intratumoral Administration and Retention of IL-2 and IL-12 Bifunctional Fusion Proteins to Drive a Systemic Immune Response (2021 Informa Connect AET Europe)

Mining for Tomorrow’s Cures: Intratumoral Administration and Retention of IL-2 and IL-12 Bifunctional Fusion Proteins to Drive a Systemic Immune Response (2021 Cytokine Summit)

Intratumoral Administration and Local Retention of IL-2/IL-12 Fusion Proteins Drive a Potent Systemic Antitumor Immune Response (2021 SITC)

Safety and Activity of CLN-081 (TAS6417) in NSCLC With EGFR Exon 20 Insertion Mutations (Ins20) (2021 ASCO)

Preliminary Safety and Activity of CLN-081 in NSCLC With EGFR Exon 20 Insertion Mutations (Ins20) (2020 ESMO)

Multicenter Phase 1/2a trial of CLN-081 (TAS6417) in NSCLC Patients with EGFR Exon 20 Insertion Mutations (2019 WCLC)